

64:961 (1991)), and others (see for example Boulikas, *J. Cell. Biochem.* 55(1):32-58 (1994)). All of these references are incorporated herein in their entirety by reference. Double basic NLSs are exemplified by that of the *Xenopus* (African clawed toad) protein, nucleoplasmin (Ala Val Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys Lys Leu Asp (SEQ ID NO:14)) (Dingwall, *et al.*, *Cell* 30:449-458, (1982); Dingwall, *et al.*, *J. Cell Biol.*, 107:641-849; (1988)). Numerous localization studies have demonstrated that NLSs incorporated in synthetic peptides or grafted onto reporter proteins or other molecules not normally targeted to the cell nucleus cause these molecules to be concentrated in the nucleus. See, e.g., Dingwall and Laskey, *Ann. Rev. Cell Biol.* 2:367-390, (1986); Bonnerot, *et al.*, *Proc. Natl. Acad. Sci. USA* 84:6795-6799, (1987); Galileo, *et al.*, *Proc. Natl. Acad. Sci. USA* 87:458-462, (1990). –

AY
Cand

On page 22, immediately preceding the claims, please insert the enclosed text entitled "SEQUENCE LISTING".

IN THE CLAIMS:

Please replace Claim 9 with the following rewritten claim:

- 9. The method according to Claim 4, wherein said Rad51 antisense molecule is selected from the group consisting of AS4, AS5, AS6, AS7, AS8 and AS9 (SEQ ID NOS:4-9). –

AS

REMARKS

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made."